Our team is made up of over 80 individuals who design and conduct multi-center clinical trials, especially for neurodegenerative and rare disorders. Over the last two decades, CHeT has been instrumental in conducting pivotal clinical trials in support of seven FDA approvals. These include first of their kind therapies for Parkinson disease, Huntington disease, and other rare disorders.
About CHeT
National leader in applying technology to transform research + care
Our team is made up of over 80 individuals who design and conduct multi-center clinical trials, especially for neurodegenerative and rare disorders. Over the last two decades, CHeT has been instrumental in conducting pivotal clinical trials in support of seven FDA approvals. These include first of their kind therapies for Parkinson disease, Huntington disease, and other rare disorders.
Pivotal trials leading to 7 FDA-approved treatments
Innovative activities to modernize clinical trials
Leading the way in creation, development, and implementation of novel technologies in care + research. Over the past 10 years, CHeT director Dr. Ray Dorsey has been involved in ~15 studies involving novel technologies including wearable sensors, smartphone technology, and telemedicine (virtual house calls and virtual research visits).
- Virtual visits and virtual clinical trials
- Novel, objective measures of disease including smartphone apps + wearable sensors
- Disease modeling
- Data visualization
- Data-driven site selection
- Risk-based monitoring
